A phase 2 trial (ClinicalTrials.gov, NCT02413489) of daratumumab in relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) subtypes, including mantle-cell lymphoma (MCL), DLBCL, and follicular lymphoma (FL), showed that this CD38 antibody is not effective as monotherapy in NHL [56]. This evidence concerns the gene CD38 and diffuse large B-cell lymphoma.